Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment

Abstract

Pneumothorax has been reported as a pazopanib-associated adverse event in patients with lung metastases of soft tissue sarcoma (STS). However, pneumothorax triggered by eribulin treatment has never been reported. We herein report two cases of spontaneous pneumothorax in patients with STS treated with eribulin. Both patients experienced pneumothorax accompanied by sudden dyspnea on day 9 or 10 of eribulin treatment. These two cases suggest that spontaneous pneumothorax may occur as an adverse event of eribulin treatment in such patients. We should therefore be alert for the potential development of pneumothorax during eribulin treatment of patients with STS and lung metastases.

Pneumothorax presentation in endometrial sarcoma patients receiving chemotherapy: A case series

“…17 Similarly, other studies and case reports of systemic therapy induced pneumothoraces include eribulin in some types of sarcomas as well as pazopanib, an anti-VEGF targeted tyrosine kinase inhibitor, which was reported and associated with a case of high grade ESS. 15,18 A subsequent study looking at the use of pazopanib in sarcoma patients concluded that it's use did not confer a higher risk of pneumothorax than those not taking pazopanib. 19 Interestingly, the only risk factor associated with a higher risk of pneumothorax on multivariate analysis was the development of cavitary lesions within lung nodules.…”